Latent vs Active TB: What a Positive Skin Test or IGRA Really Tells You

A positive tuberculin skin test or IGRA answers a narrower question than most people assume. It confirms that your immune system has met Mycobacterium tuberculosis at some point and still recognizes it. It does not say whether live bacteria remain, whether the first contact was last month or thirty years ago, or whether you are drifting toward illness. Both tests read immune memory, not a live count of bacteria, so neither one can separate latent tuberculosis infection from active TB disease. That separation comes from a clinical exam, a chest radiograph, and, when the picture warrants it, sputum testing.

Key points#

• A positive skin test or IGRA proves sensitization to TB, not that live bacteria are still present.
• Neither test distinguishes latent infection from active disease; that requires an exam and imaging.
• A blood-based IGRA is less likely than the skin test to react to prior BCG vaccination.
• Only about 5 to 10 percent of infected people ever develop TB disease over a lifetime.
• Risk is highest in the first two years after infection and rises with anything that weakens cellular immunity.

A footprint, not a photograph of the animal#

Think of a positive result as a footprint left in the mud rather than a live photograph of the animal that made it. The print proves something passed through. It cannot tell you whether the animal is still nearby, or whether it moved on long ago.

TB testing works the same way. It does not search for the bacterium directly. It reads the body's trained response to it. When immune cells that have already met M. tuberculosis antigens encounter them a second time, they release interferon-gamma and set off local inflammation. Both approved test types are built to detect that recall reaction, and nothing more.

How the two tests read the same signal#

The tuberculin skin test places purified protein derivative, a mixture of mycobacterial proteins, just under the skin of the forearm. A trained reader returns 48 to 72 hours later and measures the firm, raised area of induration, not the redness around it.

Interferon-gamma release assays run the same logic in a test tube. The FDA-approved QuantiFERON-TB Gold Plus and T-SPOT.TB mix a blood sample with synthetic peptides that imitate specific TB antigens, then measure how much interferon-gamma the cells release. Because the antigens these blood tests use (ESAT-6 and CFP-10) are not found in the BCG vaccine, an IGRA is less likely than the skin test to turn positive simply because someone was vaccinated. For that reason, the CDC lists blood tests as the preferred option for people who received BCG.

That added specificity is real, but it does not deliver what patients most want to know. A positive result by either route is a marker of sensitization. It confirms the immune system was trained. It cannot count how many bacteria remain, or whether any remain at all.

Why a positive test cannot sort latent from active#

This is the step most often misread. The CDC states it plainly: a diagnosis of latent TB infection is made when a person has a positive skin or blood test and a medical evaluation finds no evidence of TB disease. The test does not make that determination. It raises a flag; the workup decides what the flag means.

So a positive result opens an evaluation rather than closing one. Standard guidance sets out the next steps: a chest radiograph and, if disease is suspected, bacteriologic testing of sputum by smear microscopy, culture, and nucleic acid amplification. Those methods look for the organism itself and the damage it causes, which is exactly what the immune tests cannot do. It also runs the other way. Because an immune test cannot reliably rule active disease out, anyone with worrying symptoms is evaluated for disease no matter what the test shows, and a negative result never fully clears a patient who is genuinely ill.

A dimmer switch, not an on-off switch#

The tidy division between latent and active is a helpful shorthand for messier biology. Infection is better pictured as a dimmer switch than an on-off one. Along its range sit cleared contact, contained bacteria held in check by immunity, subclinical disease with few or no symptoms, and, at the far end, overt illness. A skin test or IGRA cannot place a person on that dial. Two people with identical positive results may occupy very different points, and the test predicts neither where they sit nor which way they will move. The label they eventually receive, latent or active, is assigned after the workup, not read off the result.

Judging who is likely to progress#

If the test cannot forecast progression, how is risk estimated? Through context and epidemiology rather than the reading itself.

The baseline numbers are reassuring. The WHO estimates that roughly a quarter of the world's population carries immunologic evidence of TB infection, yet only about 5 to 10 percent of infected people ever develop TB disease across a lifetime. Most positive tests never become illness. Even so, the CDC notes that in the United States, progression from untreated latent infection accounts for roughly 80 percent of TB cases, which is why finding and treating higher-risk infection is worth the effort. The scale behind those percentages is large: the WHO 2024 global report estimates 10.8 million people fell ill with TB in a single year.

Risk is concentrated rather than spread evenly. It peaks in the first two years after infection, so a recent conversion, a test that flips from negative to positive after known contact, carries far more weight than a longstanding positive. It climbs steeply with anything that blunts cellular immunity: HIV above all, but also very young age, immunosuppressive therapy, diabetes, undernutrition, and conditions such as silicosis, with the WHO adding tobacco and heavy alcohol use. A clinician weighs these factors alongside how likely the test reflects true infection and what the chest film shows, then decides whether preventive treatment makes sense, since treating latent infection is roughly 90 percent effective at heading off progression.

What a positive result should set in motion#

A positive test is a starting line, not a verdict. It should trigger a symptom review, a chest radiograph, and a candid look at personal risk factors, so that the two questions the test cannot answer, whether active disease is present now and how likely it is later, are handed to the tools that can answer them. The value printed on the report matters far less than the clinical story around it.